Drugs / Brinzolamide
Brinzolamide
also known as
Azopt · Brinzolamide/Timolol Maleate Fixed Combination · AL-4862 · AzoptTM · Brinzolamida · Brinzolamide component of azarga · Brinzolamide component of simbrinza · Brinzolamide Ophthalmic Suspension · +1 more
Small molecule targets CA2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AZOPT | — | 2006-09-28 | fda.gov ↗ |
| Approved | EU (EMA) | Azopt | — | 2000-03-09 | europa.eu ↗ |
| Approved | US (FDA) | AZOPT | — | 1998-04-01 | fda.gov ↗ |
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03896633 | Feb → Nov 2018 | open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03542006 | Jun 2018 → Jan 2019 | central serous chorioretinopathy | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01426867 | Sep → Nov 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00527501 | Aug → Dec 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 310 trials · 2 met primary | ||||||
| Phase 3 | NCT05022004 | Dec 2021 → Dec 2022 | ocular hypertension, open-angle glaucoma | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04944290 | May 2021 → Mar 2022 | ocular hypertension, open-angle glaucoma | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT01721707 | Dec 2012 → Mar 2013 | ocular hypertension, open-angle glaucoma | Adapt Produtos Oftalmológicos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01722604 | Jan → Sep 2012 | open-angle glaucoma | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT01297920 | Mar 2011 → Jun 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00767481 | Oct 2008 → Feb 2009 | glaucoma, ocular hypertension | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00314158 | Nov 2005 → Jan 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 3 | NCT00314171 | Oct 2005 → Aug 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 3 | NCT00061516 | Jan 2003 → Feb 2006 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 421 trials · 2 met primary | ||||||
| Phase 4 | NCT06883123 | May 2025 → Apr 2026 overdue | open-angle glaucoma | Prairie Eye Center | Recruiting | No outcome recorded |
| Phase 4 | NCT03150160 | Sep → Dec 2017 | glaucoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02730871 | Jun 2016 → Jul 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02419508 | Aug 2015 → Feb 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 4 | NCT02325518 | Dec 2014 → Dec 2015 | ocular hypertension, open-angle glaucoma | Alcon, a Novartis Company | Completed | No outcome recorded |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01514734 | Mar → Aug 2012 | glaucoma | Alcon Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01518244 | Dec 2011 → Feb 2013 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01340014 | Sep 2011 → Oct 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01484951 | May 2011 → Mar 2012 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01263444 | Mar 2011 → Apr 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01111890 | Apr 2010 → Jul 2011 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01055366 | Mar 2010 → Dec 2011 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00869141 | Mar 2009 → Mar 2013 | glaucoma | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00800540 | Feb 2009 → Jan 2012 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00759941 | Oct 2007 → Jul 2009 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00382226 | Sep 2006 → Aug 2007 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00300079 | Sep 2006 → Sep 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00758342 | May 2006 → Mar 2008 | — | Alcon Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00372827 | Feb 2004 → Jan 2006 | ocular hypertension, open-angle glaucoma, pigment dispersion syndrome | Alcon Research | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT00121147 | Sep 2003 → Oct 2005 | exfoliation syndrome, ocular hypertension, open-angle glaucoma | Hermann Eye Center | Completed | No outcome recorded |
| Comparator or background therapy21 trials | ||||||
| Phase 2 | NCT03763227 Comparator | Jul 2015 → Aug 2019 | inherited retinal dystrophy | Sultan Qaboos University | Completed | No outcome recorded |
| Phase 2 | NCT02140060 Comparator | Jun → Nov 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00961649 Comparator | Oct 2009 → Feb 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT04024072 Comparator | Jun 2019 → Feb 2020 | ocular hypertension, open-angle glaucoma | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02339584 Comparator | Apr 2015 → Nov 2016 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01310777 Comparator | May 2011 → Jan 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01309204 Comparator | May 2011 → Jan 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 3 | NCT01297517 Comparator | Feb 2011 → Mar 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 3 | NCT01357616 Comparator | Nov 2010 → Jan 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01004900 Comparator | Jun 2009 → Mar 2011 | glaucoma | Singapore Eye Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00767494 Comparator | Oct 2008 → Feb 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00980473 Comparator | Sep 2007 → Sep 2011 | glaucoma | Singapore National Eye Centre | Unknown | No outcome recorded |
| Phase 4 | NCT01312402 Comparator | Jan 2011 → Mar 2014 | pathologic nystagmus | Akron Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01471158 Comparator | Sep 2010 → May 2011 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00761995 Comparator | Feb 2009 → Jul 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00471380 Comparator | Mar 2007 → Oct 2008 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00440141 Comparator | Jul 2006 → Mar 2007 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00675207 Comparator | Jan 2006 → Jul 2007 | ocular hypertension, open-angle glaucoma | Northwestern Ophthalmic Institute S.C. | Completed | No outcome recorded |
| — | NCT04523844 Comparator | May → Jul 2020 | ocular hypertension | General Hospital of Athens Elpis | Completed | No outcome recorded |
| — | NCT03494257 Comparator | Sep 2017 → Mar 2018 | cataract | University Hospital of Patras | Completed | No outcome recorded |
| — | NCT01084902 Comparator | Feb → Sep 2010 | ocular hypertension | Peking University First Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-11-15 | Novartis Pharmaceuticals | Results Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting novartis.com ↗
Findings show additive effect of BBFC therapy in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled on PGA alone. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-11-15 | Novartis Pharmaceuticals | Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting novartis.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brinzolamide | “a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID)” NCT01535768 ↗51“Brinzolamide Ophthalmic Suspension, 1% (Azopt), a carbonic anhydrase inhibitor” NCT00121147 ↗ “alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.” NCT04296916 ↗ “oral acetazolamide 500mg/day or topical brinzolamide twice daily” NCT03763227 ↗ “brinzolamide and brimonidine tartrate” NCT06883123 ↗ “AZOPT (brinzolamide)” NCT00061516 ↗ |
| Known as | AL-4862 | ChEMBL registry synonym — accepted as the source's own label CHEMBL220491 ↗ |
| Known as | Azopt | “This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive...” NCT00300079 ↗12“Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt® (Brinzolamide) Ophthalmic Suspension 1%” NCT05022004 ↗ “Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)” NCT00758342 ↗ “Brinzolamide Ophthalmic Suspension, 1% (Azopt), a carbonic anhydrase inhibitor” NCT00121147 ↗ “Brinzolamide 1% ophthalmic solution (Azopt)” NCT00759941 ↗ “Topical brinzolamide (Azopt) versus placebo” PMID 25336575 ↗ Oct 2014 |
| Known as | AzoptTM | “AzoptTM (brinzolamide ophthalmic suspension 1%)” NCT01722604 ↗ |
| Known as | Brinzolamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL220491 ↗ |
| Known as | Brinzolamide component of azarga | ChEMBL registry synonym — accepted as the source's own label CHEMBL220491 ↗ |
| Known as | Brinzolamide component of simbrinza | ChEMBL registry synonym — accepted as the source's own label CHEMBL220491 ↗ |
| Known as | Brinzolamide Ophthalmic Suspension | “Brinzolamide Ophthalmic Suspension, 1% (Azopt), a carbonic anhydrase inhibitor” NCT00121147 ↗ |
| Known as | Brinzolamide/Timolol Maleate Fixed Combination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01471158 ↗ |
| Known as | NSC-760050 | ChEMBL registry synonym — accepted as the source's own label CHEMBL220491 ↗ |
| Action | Inhibit | “Brinzolamide Ophthalmic Suspension, 1% (Azopt), a carbonic anhydrase inhibitor” NCT00121147 ↗1“Carbonic anhydrase II inhibitor” CHEMBL220491 ↗ |
| Modality | Small molecule | — CHEMBL220491 ↗ |
| Route | Topical | “Topical carbonic anhydrase inhibitors (Brinzolamide)” NCT00121147 ↗ |
| Target | CA2 | “Carbonic anhydrase II inhibitor” CHEMBL220491 ↗ |